@article{TLCR31044,
author = {Yangyang Xu and Bing Wan and Xi Chen and Ping Zhan and Yuan Zhao and Tianli Zhang and Hongbing Liu and Muhammad Zubair Afzal and Said Dermime and Steven N. Hochwald and Paul Hofman and Hossein Borghaei and Dang Lin and Tangfeng Lv and Yong Song and written on behalf of AME Lung Cancer Collaborative Group},
title = {The association of PD-L1 expression with the efficacy of anti- PD-1/PD-L1 immunotherapy and survival of non-small cell lung cancer patients: a meta-analysis of randomized controlled trials},
journal = {Translational Lung Cancer Research},
volume = {8},
number = {4},
year = {2019},
keywords = {},
abstract = {Background: We conducted a meta-analysis to evaluate the efficacy of anti-programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) monotherapy or immunotherapy combined with chemotherapy and further estimated the value of PD-L1 expression in predicting the response from anti-PD-1/PD-L1 treatments as monotherapy or in combination with chemotherapy.
Methods: Clinical trial data were searched from electronic databases, which evaluated PD-1/PD-L1 inhibitors in non-small cell lung cancer (NSCLC) and correlated with PD-L1 expression levels.
Results: Fifteen randomized-controlled trials involving 10,074 patients were identified. Comparing anti- PD-1/PD-L1 monotherapy to chemotherapy, the pooled HR for overall survival (OS) was 0.77 (95% CI: 0.69–0.85, P},
issn = {2226-4477}, url = {https://tlcr.amegroups.org/article/view/31044}
}